Loading...
Loading...
Gilead Sciences, Inc.
GILD today announced that a Phase 2 clinical
trial evaluating tenofovir alafenamide fumarate (TAF; formerly referred to as
GS-7340), an investigational novel prodrug of tenofovir for the treatment of
HIV-1 infection, met its primary objective. The ongoing study compares a
once-daily single tablet regimen containing TAF 10 mg/elvitegravir 150
mg/cobicistat 150 mg/emtricitabine 200 mg with Stribild^TM (elvitegravir 150
mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300
mg) among treatment-naïve adults. The TAF-based regimen achieved a similar
virologic response to Stribild based on the proportion of patients with HIV
RNA levels (viral load) of less than 50 copies/mL at 24 weeks of therapy (87
percent versus 90 percent, respectively).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in